Asset profile
Piclidenoson
Small molecule
Evidence outlook · lead readout
NCT03168256 · Plaque Psoriasis
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT03168256: Randomized, double-blind Phase 3 study (n=529) meeting primary endpoint at week 16 with sustained efficacy through week 32 (PMID 38279575).
Also in development:Plaque Psoriasis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 61 same-indication; 27 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Piclidenoson: this drug | Phase 3 | Small molecule | Adenosine A3 receptor | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | ||
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | ||
| Brodalumab (Siliq) | Approved | Monoclonal antibody | IL-17 receptor A | ||
| Calcipotriene / Betamethasone Dipropionate Cream (Wynzora) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Calcipotriene / Betamethasone Dipropionate Foam (Enstilar) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| Desoximetasone (Topicort Spray) | Approved | Small molecule | Glucocorticoid receptor agonist | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | ||
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Halobetasol Propionate Foam (Lexette) | Approved | Small molecule | Glucocorticoid receptor | ||
| Halobetasol Propionate Lotion (Bryhali) | Approved | Small molecule | Glucocorticoid receptor |
…and 47 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.